NeuroBo Pharmaceuticals Announces Joint Research Agreement With Dong-A ST Co. Ltd. And ImmunoForge To Develop Long-Acting Once-Monthly Formulation Of DA-1726 For Treatment Of Obesity
Portfolio Pulse from Benzinga Newsdesk
NeuroBo Pharmaceuticals has announced a joint research agreement with Dong-A ST Co. Ltd. and ImmunoForge to develop a long-acting, once-monthly formulation of DA-1726 for the treatment of obesity.
August 06, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroBo Pharmaceuticals has entered into a joint research agreement with Dong-A ST Co. Ltd. and ImmunoForge to develop a long-acting, once-monthly formulation of DA-1726 for the treatment of obesity.
The partnership to develop a new obesity treatment could significantly enhance NeuroBo's product portfolio and market position, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100